PTO/SB/08x (08-03.)
Approved for use through 07/31/2006 OMS 0851-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE; to a collection of information unless it contains a valid OMS control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09955394
Filing Date		2001-17-09
First Named Inventor	Scott	
Art Unit		3624
Examiner Name	Weisberger	
Attorney Docket Number		FINA.00410

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Releva		Lines where ges or Relev			
	1										
If you wisl	h to ac	l dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1										
If you wisl	h to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	d button	Add		
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	ть
	1	04193658	JP			1992-07-21	Hitachi				
	2	05082102	JP			1993-08-04	OKI Electric Ind				
	3	05177511	JP			1993-06-25	Nec Corp				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09955394
Filing Date		2001-17-09
First Named Inventor	Scott	
Art Unit		3624
Examiner Name	Weis	berger
Attorney Docket Number		FINA 00410

	4	2306713	GB		1997-07-05	Friend et al				
	5	0105793	wo		2001-07-12	Jacobsen et al.				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
			NON-PATER	AT LITE	RATURE DO	CUMENTS	Remove			
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when appropr date, pages(s), volume-is:		T 5		
	1	ANONYMOUS, "Interac	NONYMOUS, "Interactive Software Eases 401 (ix) Planning." Bank Marketing, V26, No. 10, 1994, p. 56							
	2	AUTHOR UNKNOWN, "Interactive Variable Control During Visualization of Mathematical Functions," IBM Technical Disclosure Bulletin, Vol. 34. No. 9, 1992; pp. 289/299.								
	3 AUTHOR UNKNOWN. "Microsoft Excel 97 Intermediate." Cheltenham Computer Training 1995 - 2001. www. cdglobal com. pp. 26-30.									
	4	BOWERS, N.L., "Actuarial Mathematics." The Society of Actuaries. 1986; pp. 52-59.								
	5	CARHART, M., "On Persistence in Mutual Fund Performance." The Journal of Finance. Vol. 52. No.1. 1997, pp. 57-82.								
	6	KARIYA, T., "Elements of Financial Science." Toyo Keizai Shimpo, K.K., September 25, 1997, pp. 71-101 (Chapter 5) and pp. 117-133 (Chapter 7).								
	7	MURRAY, G.W. et al., "Practical Optimization." Academic Press. Chapter 5: 1981.								

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09955394
Filing Date		2001-17-09
First Named Inventor Scott		
Art Unit		3624
Examiner Name Weist		berger
Attorney Docket Number		FINA.00410

	8	SHARPE, W.F., "AAT Asset Allocation Tools." T	he Scientific Press, 1985, pp. 84-85; pp. 93-96					
	9	SOCIETY OF ACTUARIES, *1994 Group Annul 1994, pp. 865-913.	y Mortality Table and 1994 Group Annuity Reserving Table." Vol. 47.					
	10	*Net Results TM, Your On-Line Financial Adviso of 1997.	r*, downloaded from website http://www.isnetwork.com, in December					
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner	Examiner Signature Date Considered							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kink Codes of USPTO Patent Documents at view (ISPTD, COV) or MEPP 901.04. * Enter office that issued the document, by the No-tellar Code (WIPO Standard ST3.) * For Laplanese patent for Journals*, the includation of the parent for the Emperor many process the serial number of the patent document. * Mind of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. * Applicant is to place a check mark there if Empirish targuages translation an attached.*

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09955394
Filing Date		2001-17-09
First Named Inventor	Scott	
Art Unit		3624
Examiner Name	Weis	berger
Attorney Docket Numb	er	FINA 00410

39 957

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CPR 1.56(c) more than three months prior to the filing of the information disclosure that the contained in the contained in

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Michael A DeSanctis

7 None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.					
	Signature	/Michael A. DeSanctis/	Date (YYYY-MM-DD)	2006-10-15	

Registration Number

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operament of Commence, P. 0. 80x 1450, Alexandri, V.3.231-1450, D. ON TO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA.2231-4450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.